Internal Medicine, Medical Oncology · Hackensack, NJ
NPI
1376502237
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
92 2nd St
Hackensack, NJ, 07601
Phone (551) 996-5811
Groups this clinician bills Medicare through
Medicare paid, 2024
$473K
59,229 services
Medicare patients, 2024
872
Average age 74
Drug cost, 2024
$4.4M
1,678 prescriptions
Company payments, 2025
$885
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Donna M McNamara was code Q5110 (injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram), 31,980 times for 13 patients. In total Donna M McNamara billed 59,229 services in 49 codes, and Medicare paid $473K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-01-26.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 31,980 | 13 | $0.22 | $6,884 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,774 | 720 | $13.76 | $24K |
| 99214 Office E&M - Established | Office | 1,252 | 656 | $102.89 | $129K |
| Q5111 Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | Office | 744 | 27 | $106.39 | $79K |
| 99215 Office E&M - Established | Office | 579 | 192 | $150.45 | $87K |
| Q5108 Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | Office | 420 | 13 | $109.54 | $46K |
| 99213 Office E&M - Established | Office | 366 | 152 | $75.65 | $28K |
| 96372 Injection Administration | Office | 265 | 49 | $12.03 | $3,187 |
| 99232 Hospital E&M - Subsequent | Facility | 236 | 80 | $66.25 | $16K |
| 99205 Office E&M - New | Office | 67 | 67 | $184.96 | $12K |
| 99222 Hospital E&M - Initial | Facility | 12 | 12 | $110.20 | $1,322 |
By year: 2022 $467K for 34,992 services; 2023 $453K for 53,036 services; 2024 $473K for 59,229 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,070 | 396 | $7.61 | $8,138 |
| 85027 Blood Count | 395 | 202 | $6.29 | $2,485 |
Medicare prescription drug claims, 2024
In 2024, the drug Donna M McNamara prescribed most often to Medicare patients was Anastrozole, with 691 prescriptions and refills. In total Donna M McNamara wrote 1,678 Medicare prescriptions that cost $4.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 691 | 1,966 | 241 | $16K |
| Letrozole Generic | 182 | 495 | 67 | $4,794 |
| Ondansetron Hcl Generic | 99 | 99 | 62 | $643 |
| Ibrance Palbociclib | 77 | 77 | Under 11 | $1.2M |
| Exemestane Generic | 67 | 198 | 22 | $16K |
| Prochlorperazine Maleate Generic | 66 | 66 | 47 | $678 |
| Verzenio Abemaciclib | 58 | 58 | Under 11 | $944K |
| Lynparza Olaparib | 55 | 55 | Under 11 | $750K |
| Ibandronate Sodium Generic | 41 | 93 | 15 | $1,015 |
| Gabapentin Generic | 38 | 62 | 16 | $264 |
| Zejula Niraparib Tosylate | 33 | 33 | Under 11 | $617K |
| Kisqali Ribociclib Succinate | 25 | 26 | Under 11 | $381K |
| Eliquis Apixaban | 24 | 30 | Under 11 | $17K |
| Tamoxifen Citrate Generic | 21 | 45 | Under 11 | $350 |
| Lenvima Lenvatinib Mesylate | 11 | 11 | Under 11 | $254K |
Brand drugs: - claims; generic drugs: 1,362 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Donna M McNamara $885 ($885 in general payments such as food, travel and fees) from 11 companies. The largest payer was Daiichi Sankyo Inc. with $314.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.